Flow cytometric analysis of PHA-treated Human PBMC labelling CD357 antibody at 1/100 (2 μg) dilution (Right panel) or untreated (Left panel). Goat Anti-Mouse IgG Alexa Fluor® 647 was used as the secondary antibody. Then cells were stained with CD25 - Brilliant Violet 421™ antibody separately.
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD357 |
| Synonyms | Tumor necrosis factor receptor superfamily member 18; Activation-inducible TNFR family receptor; Glucocorticoid-induced TNFR-related protein; AITR; GITR; TNFRSF18 |
| Location | Secreted, Cell membrane |
| Accession | Q9Y5U5 |
| Clone Number | S-3126 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2b,k |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | PHA-treated Human PBMC |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1:100 | Hu |
Background
CD357, synonymous with GITR (glucocorticoid-induced TNFR-related protein) and TNFRSF18, is a type I transmembrane receptor of the tumor necrosis factor receptor superfamily that is constitutively expressed on CD25⁺CD4⁺ regulatory T cells and up-regulated on activated CD4⁺ and CD8⁺ T cells, NK cells, APCs and many tumors; upon binding its ligand TNFSF18 it recruits TRAF2 and TRAF5, triggering NF-κB and MAPK signaling that enhances effector T-cell proliferation, cytokine production and resistance to suppression by Tregs, positioning CD357 as a promising co-stimulatory target in cancer immunotherapy .
Picture
Picture
FC
